GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reports a transaction by senior manager Maya Martinez‑Davis, who serves as President. She acquired 9.407 notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan account at a price of $50.7600 per ADS.
The notional ADS are linked to GSK’s ADS and were acquired on 22 July 2026 on the New York Stock Exchange (XNYS). The transaction is described as a single transaction in ADS with ISIN US37733W2044.
GSK plc reports that additional ordinary shares have been admitted to trading on the London Stock Exchange Main Market under existing block listing arrangements. The admission relates to the GlaxoSmithKline plc Share Save Plan 2022.
70,759 Ordinary Shares of 31¼ pence each were admitted, increasing the total number of Ordinary Shares admitted to trading to 4,316,292,310. The notification covers the period from 29 May 2026 to 24 July 2026, and the new shares are fully fungible with existing Ordinary Shares.
GSK plc reports that the US Food and Drug Administration has approved Jideytro (zidesamtinib), a ROS1 selective kinase inhibitor, for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have received a prior ROS1 kinase inhibitor. The decision comes ahead of the original target action date of 18 September 2026 and follows Breakthrough Therapy and Orphan Drug Designations.
The approval is based on the global single-arm ARROS-1 phase I/II trial in previously ROS1 inhibitor-treated patients, where among 117 patients the objective response rate was 44% and duration of response rates were 82% at six months and 69% at 12 months. A pooled safety population of 446 patients showed common adverse reactions including oedema, peripheral neuropathy, constipation, fatigue and dyspnoea.
Jideytro is GSK’s first approved lung cancer medicine and originates from the recently completed acquisition of Nuvalent, Inc. GSK also highlights additional targeted oncology programmes, including neladalkib (NVL-655) for ALK-altered NSCLC with a US FDA target decision date of 27 November 2026, NVL-330 for HER2-altered NSCLC, and the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) in late-stage development.
GSK reports that the European Medicines Agency has accepted a submission to update the label for Bexsero to include a single-dose booster for individuals aged 10 years and older who were previously vaccinated with Bexsero. If approved, this booster could help reduce the burden of Invasive Meningococcal Disease (IMD) in countries with established infant MenB programmes.
The submission is supported by a Phase 3b, open-label, multicentre study in 10 to 20-year-olds showing one booster dose effectively boosted immune responses in those vaccinated as infants. IMD is a rare, life‑threatening disease with a fatality rate of 4–20%, and up to 20% of survivors experience severe, life-changing sequelae. In 2024, serogroup B caused 56% of IMD cases under age 65 in the EU/EEA. Bexsero is registered in 61 countries, included in multiple European immunisation programmes, and around 138 million doses have been distributed globally since 2015.
GSK plc announces that, following a competitive tender process led by its Audit & Risk Committee, the Board has decided to re-appoint Deloitte LLP as external auditor from the financial year ending 31 December 2028. Deloitte was initially appointed for the financial year ended 31 December 2018.
As a Public Interest Entity, GSK is required to tender its statutory audit every 10 years and rotate auditor every 20 years. A resolution to re-appoint Deloitte with effect from the 2028 financial year will be put to shareholders for approval at the 2028 Annual General Meeting, with further details to appear in GSK’s 2026 Annual Report.
GSK plc reported mixed Phase III results for camlipixant in adults with refractory chronic cough. In the 52-week CALM-1 study, camlipixant 50mg twice daily achieved the primary endpoint, showing statistically significant reductions in 24-hour cough frequency versus placebo at week 12.
In the 24-week CALM-2 study, the same 50mg dose did not reach statistical significance at week 24, and the 25mg twice-daily dose was not significant in either trial. Key secondary endpoints, including the Chronic Cough Diary measure, were not met. With overall safety similar to placebo but efficacy deemed unlikely to transform patient care, GSK will not progress camlipixant further in RCC, while continuing the Phase IIb BALANCE trial in irritable bowel syndrome.
GSK plc reported that several senior leaders and non-executive directors acquired small amounts of American Depositary Shares (ADS) through the automatic re-investment of cash dividends paid to shareholders on 9 July 2026. The ADSs trade on the New York Stock Exchange.
On 10 July 2026, multiple directors, including Maya Martinez-Davis and several independent non-executive directors, acquired ADSs at prices of $52.4700 and $52.7353 per ADS. On 14 July 2026, executives including James Ford, Maya Martinez-Davis and Shobie Ramakrishnan received additional ADSs at $51.6696 per ADS, all as single transactions executed on the NYSE.
GSK plc has completed its acquisition of Nuvalent, Inc., a Boston-based clinical-stage biopharmaceutical company developing precisely targeted oncology therapies. The deal adds three lung cancer assets to GSK’s portfolio, strengthening its planned expansion from blood and women’s cancers into lung and other solid tumours.
The transaction was executed via a tender offer for all of Nuvalent’s outstanding shares, with an aggregate equity value of $10.6 billion (£8.0 billion). Net of cash acquired, GSK’s aggregate investment is approximately $9.4 billion (£7.1 billion). The acquisition includes zidesamtinib (NVL-520) and neladalkib (NVL-655), both under FDA review for specific forms of non-small cell lung cancer and holding Breakthrough Therapy and Orphan Drug Designations, which GSK states are expected, if approved, to launch in 2026 with multi-blockbuster potential. It also brings NVL-330, in phase I for HER2-altered non-small cell lung cancer.
GSK plc reports multiple acquisitions of ordinary shares and American Depositary Shares by senior management and persons closely associated, through reinvestment of dividends paid on 9 July 2026. Named participants include the chief executive officer, chief financial officer, several business presidents and other senior officers.
The acquisitions and increases in notional interests took place on 9, 10 and 13 July 2026 on the London Stock Exchange and New York Stock Exchange at prices around £19.6297 and £19.5950 per ordinary share and $52.4700 per ADS, including holdings within ISAs and positions in the company’s Deferred Annual Bonus Plan.
GSK plc reports multiple acquisitions of its ordinary shares of 31 ¼ pence each (ISIN GB00BN7SWP63) by senior management and persons closely associated with them. These transactions occurred on 9 July 2026 on the London Stock Exchange at prices around £19.6290 per share.
Lynn Baxter (President, Europe), Julie Brown (Chief Financial Officer), James Ford (SVP and Group General Counsel), David Redfern (President, Corporate Development), Regis Simard (President, Global Supply Chain), Philip Thomson (President, Global Affairs), Deborah Waterhouse (CEO, ViiV Healthcare and President, Global Health), Victoria Whyte (SVP & Company Secretary), and PCA Neil Falkingham each acquired small share amounts under GSK’s Share Reward Plan, typically 12–14 shares per person combining partnership and matching shares.
In addition, Luke Miels (Chief Executive Officer) and several of the same executives and PCAs acquired further ordinary shares through the re-investment of dividends paid on 9 July 2026 on holdings within the Share Reward Plan, with individual acquisitions ranging from a few shares to over 1,000 shares in a single transaction.